Tailoring Prevention in Reducing ASCVD Risk: Who, What, How, and Why?

New data & guidelines are changing the management of patients with established ASCVD. Join our experts and improve outcomes for your at-risk patients.

Live Meeting
1.50 available credits
Information
April 28, 2022
06:30 PM - 08:30 PM CDT
Marriott Marquis Chicago
Grand Horizon Ballroom A & B - 2121 S Prairie Ave, Chicago, Illinois, United States
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    Patients with established ASCVD are at increased risk of myocardial infarction, stroke, and death. While many of these patients will be managed by family practitioners, others may be referred to cardiologists, internists, and endocrinologists. These clinicians require frequent updates on the data and management of lipid disorders so that new paradigms can be incorporated into the clinical setting. Take part in our effective case-based learning that simulates clinical practice so that you can keep up with the changing landscape of ASCVD.

  • Program Schedule*

    Click Here to Download the Presentations

    6:30 pm–7:00 pm

    Registration and Buffet Dinner

    7:00 pm–7:05 pm

    Welcome, Introductions, Program Overview
    Eliot Brinton, MD
    Program Chair

    7:05 pm–7:20 pm

    Update on Determining Risk Status in ASCVD
    James Underberg, MD

    7:20 pm–7:40 pm

    Recent Evidence from REDUCE-IT: Latest Clinical Trials
    Deepak Bhatt, MD, MPH

    7:40 pm–7:55 pm

    Differential Biological Effects of Omega-3 Fatty Acids
    Eliot Brinton, MD

    7:55 pm–8:15 pm

    Practical Considerations to Manage Residual Risk;
     Case Presentations
    Eliot Brinton, MD and James Underberg, MD

    8:15 pm–8:25 pm

    Questions & Answers
    All Faculty

    8:25 pm–8:30 pm

    Post-activity Test Questions, Closing Comments, Adjourn
    Eliot Brinton, MD

    *Subject to Change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity,

    Program Chair:

    Eliot A. Brinton, MD
    President
    Utah Lipid Center
    Salt Lake City, UT
    Consulting Fees: Amarin, Amgen, Boehringer, Esperion, Kowa, Merck, Nova, Regeneron, Sanofi

    Faculty:

    Deepak L. Bhatt, MD, MPH
    Executive Director, Interventional Cardiovascular Programs
    Professor of Medicine, Brigham and Women’s Hospital Heart & Vascular Center
    Harvard Medical School
    Boston, MA
    Research: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    James A. Underberg, MD, MS
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of
    Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    Immediate Past President, National Lipid Association
    New York, NY
    Consulting Fees: Alexion, Amarin, Amgen, Amyrt, Esperion, Novartis
    Research: Amyrt Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Exhibit greater competence in stratifying patients at risk of future ASCVD events
    • Differentiate various omega-3 formulations in clinical practice based on the evidence of impact on ASCVD risk in the most recent clinical trials
  • Target Audience

    This activity is designed to meet the educational needs of internists, primary care physicians, hospitalists, and allied healthcare professionals, including pharmacists, nurse practitioners, physician assistants, dietitians, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 90 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Details
Presenters
Comments
  • Overview

    Patients with established ASCVD are at increased risk of myocardial infarction, stroke, and death. While many of these patients will be managed by family practitioners, others may be referred to cardiologists, internists, and endocrinologists. These clinicians require frequent updates on the data and management of lipid disorders so that new paradigms can be incorporated into the clinical setting. Take part in our effective case-based learning that simulates clinical practice so that you can keep up with the changing landscape of ASCVD.

  • Program Schedule*

    Click Here to Download the Presentations

    6:30 pm–7:00 pm

    Registration and Buffet Dinner

    7:00 pm–7:05 pm

    Welcome, Introductions, Program Overview
    Eliot Brinton, MD
    Program Chair

    7:05 pm–7:20 pm

    Update on Determining Risk Status in ASCVD
    James Underberg, MD

    7:20 pm–7:40 pm

    Recent Evidence from REDUCE-IT: Latest Clinical Trials
    Deepak Bhatt, MD, MPH

    7:40 pm–7:55 pm

    Differential Biological Effects of Omega-3 Fatty Acids
    Eliot Brinton, MD

    7:55 pm–8:15 pm

    Practical Considerations to Manage Residual Risk;
     Case Presentations
    Eliot Brinton, MD and James Underberg, MD

    8:15 pm–8:25 pm

    Questions & Answers
    All Faculty

    8:25 pm–8:30 pm

    Post-activity Test Questions, Closing Comments, Adjourn
    Eliot Brinton, MD

    *Subject to Change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity,

    Program Chair:

    Eliot A. Brinton, MD
    President
    Utah Lipid Center
    Salt Lake City, UT
    Consulting Fees: Amarin, Amgen, Boehringer, Esperion, Kowa, Merck, Nova, Regeneron, Sanofi

    Faculty:

    Deepak L. Bhatt, MD, MPH
    Executive Director, Interventional Cardiovascular Programs
    Professor of Medicine, Brigham and Women’s Hospital Heart & Vascular Center
    Harvard Medical School
    Boston, MA
    Research: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    James A. Underberg, MD, MS
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of
    Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    Immediate Past President, National Lipid Association
    New York, NY
    Consulting Fees: Alexion, Amarin, Amgen, Amyrt, Esperion, Novartis
    Research: Amyrt Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Exhibit greater competence in stratifying patients at risk of future ASCVD events
    • Differentiate various omega-3 formulations in clinical practice based on the evidence of impact on ASCVD risk in the most recent clinical trials
  • Target Audience

    This activity is designed to meet the educational needs of internists, primary care physicians, hospitalists, and allied healthcare professionals, including pharmacists, nurse practitioners, physician assistants, dietitians, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 90 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free